UY39313A - Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire - Google Patents

Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire

Info

Publication number
UY39313A
UY39313A UY0001039313A UY39313A UY39313A UY 39313 A UY39313 A UY 39313A UY 0001039313 A UY0001039313 A UY 0001039313A UY 39313 A UY39313 A UY 39313A UY 39313 A UY39313 A UY 39313A
Authority
UY
Uruguay
Prior art keywords
treatment
airborne
viral infections
cov
buffering compositions
Prior art date
Application number
UY0001039313A
Other languages
English (en)
Inventor
Abid Masood Mohammed
Original Assignee
Phoxgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2010271.1A external-priority patent/GB202010271D0/en
Priority claimed from GBGB2013976.2A external-priority patent/GB202013976D0/en
Priority claimed from GBGB2018446.1A external-priority patent/GB202018446D0/en
Priority claimed from GBGB2018571.6A external-priority patent/GB202018571D0/en
Priority claimed from GBGB2020320.4A external-priority patent/GB202020320D0/en
Priority claimed from GBGB2105509.0A external-priority patent/GB202105509D0/en
Application filed by Phoxgen Ltd filed Critical Phoxgen Ltd
Publication of UY39313A publication Critical patent/UY39313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención hace referencia a una composición amortiguadora que tiene un pH de 6,7 a 7,9 a una temperatura de 37 °C para su uso en el tratamiento, el tratamiento profiláctico o la mejora de una infección viral transmitida por el aire, o para su uso en la reducción de la replicación viral en un sujeto infectado con, o expuesto a, un virus transmitido por el aire. Los virus transmitidos por el aire incluyen los virus de ARN, tales como los coronavirus, por ejemplo, MERS-CoV, SARS-CoV y SARS-CoV-2.
UY0001039313A 2020-07-03 2021-07-02 Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire UY39313A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB2010271.1A GB202010271D0 (en) 2020-07-03 2020-07-03 Viral infections
GBGB2013976.2A GB202013976D0 (en) 2020-09-05 2020-09-05 Viral infections
GBGB2018446.1A GB202018446D0 (en) 2020-11-24 2020-11-24 Viral infections
GBGB2018571.6A GB202018571D0 (en) 2020-11-25 2020-11-25 Viral infections
GBGB2020320.4A GB202020320D0 (en) 2020-12-21 2020-12-21 Viral infections
GBGB2105509.0A GB202105509D0 (en) 2021-04-18 2021-04-18 Viral infections

Publications (1)

Publication Number Publication Date
UY39313A true UY39313A (es) 2022-01-31

Family

ID=76920766

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039313A UY39313A (es) 2020-07-03 2021-07-02 Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire

Country Status (10)

Country Link
US (1) US20230301948A1 (es)
EP (1) EP4175503A1 (es)
JP (1) JP2023531568A (es)
AU (1) AU2021298896A1 (es)
BR (1) BR112022026880A2 (es)
IL (1) IL299572A (es)
MX (1) MX2023000242A (es)
TW (1) TW202207952A (es)
UY (1) UY39313A (es)
WO (1) WO2022003200A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137159A2 (en) * 2022-01-13 2023-07-20 Noor Brands Company, Llc Spray compositions and methods of use
CN114904006B (zh) * 2022-05-27 2023-10-17 中农威特生物科技股份有限公司 一种***抗原热稳定性保护剂及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711918A (en) * 1980-06-24 1982-01-21 Tokai Daigaku Remedy for herpes virus infection in human bodies
FR2616065A1 (fr) * 1987-06-02 1988-12-09 Pabst Jean Yves Aerosol pharmaceutique a base d'ammonium quaternaires
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
ES2350330T3 (es) * 2000-06-07 2011-01-21 Watson Pharmaceuticals, Inc. Tratamiento de la hiperactividad del músculo liso con (r)-oxibutinina y (r)-desetiloxibutinina.
US20130156871A1 (en) * 2011-12-20 2013-06-20 Water Pik, Inc. Nasal Wash Solution
US20150231095A1 (en) * 2013-04-18 2015-08-20 Steven A. Melman Antimicrobial compositions and uses therefore
WO2015073648A1 (en) 2013-11-13 2015-05-21 Thomas Daly Biological buffers with wide buffering ranges
WO2017212422A1 (en) * 2016-06-08 2017-12-14 Novartis Consumer Health Sa Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions
US11013687B1 (en) * 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2

Also Published As

Publication number Publication date
WO2022003200A1 (en) 2022-01-06
MX2023000242A (es) 2023-03-03
JP2023531568A (ja) 2023-07-24
US20230301948A1 (en) 2023-09-28
TW202207952A (zh) 2022-03-01
AU2021298896A1 (en) 2023-02-16
IL299572A (en) 2023-02-01
BR112022026880A2 (pt) 2023-03-14
EP4175503A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
CO2022015415A2 (es) Aplicación antiviral de análogo de nucleósido o formulación combinada que contiene análogo de nucleósido
CL2020000685A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de estos.
GT201300093A (es) Compuestos antivirales
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
UY34983A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
CO6390076A2 (es) Inhibidores de hcv ns5a
BRPI0716483B8 (pt) compostos inibidores do vírus da hepatite c e composição farmacêutica que os compreende
BR112018071048A2 (pt) combinações e métodos que compreendem um inibidor da montagem de capsídeos
WO2022217154A3 (en) Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
BR112022017243A2 (pt) Lactoferrina para uso oral com ação antiviral
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
CO2023017300A2 (es) Compuestos moduladores de diacilglicerol quinasa
DOP2014000034A (es) Compuestos de benzofurano para su uso en el tratamiento de infecciones por el virus de hepatitis c (hcv)
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
WO2020035609A3 (en) Immunogenic compositions and uses thereof
MX2020003473A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
CL2021002307A1 (es) Uso de virus oncolíticos para el tratamiento del cáncer
AR074483A1 (es) Composiciones, metodos y usos para inducir al crecimiento viral
BR112013007700A2 (pt) formas em estado sólido de um potente inibidor de hcv